ACLX Arcellx, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biotech developing novel D-Domain powered CAR-T immunotherapies for cancer and autoimmune diseases
• • New emphasis: ARC-SparX universal CAR-T platform and expanded non-oncology trials including Phase 1 generalized Myasthenia Gravis (gMG) dosing in 2025
• • Strategic shift: Pending acquisition by Gilead at $115/share plus $5 CVR contingent payment tied to $6B anito-cel sales milestone by 2029
• • Quantitative highlight: 117 patients dosed in pivotal Phase 2 iMMagine-1 trial with 96% overall response rate and PDUFA date set for Dec 23, 2026
• • Noteworthy fact: First filing of Biologics License Application (BLA) submitted and accepted for anito-cel in fourth line or later relapsed/refractory multiple myeloma

Risk Factors

• • Regulatory risk: Hart-Scott-Rodino Antitrust Act clearance required for Gilead merger, with timing and approval uncertainty risking deal abandonment
• • Macroeconomic risk: Global pandemics and U.S. trade policy changes may disrupt operations and third-party providers critical to business
• • Operational risk: Dependency on Kite for development and manufacturing of certain product candidates, risking supply interruptions or quality issues
• • Market disruption risk: Significant competition from other biotech/pharma companies threatens market share and operating results
• • Financial risk: Accumulated deficit of $725.8M with net losses $228.9M in 2025, requiring substantial additional funding to continue operations and development

Management Discussion & Analysis

• • No revenue or profitability data disclosed in this section
• • No segment or product line performance details provided
• • No changes in cash position, operating cash flow, or capital deployment mentioned
• • No management commentary on near-term outlook or updated guidance included

Risk Factors

• • New FDA clinical hold risk on anito-cel triggered by previous partial hold requires costly and time-consuming mitigation measures
• • Net loss $170.8M for nine months ended Sept 30, 2025 vs $60.3M prior year, reflecting increased R&D and operational costs
• • FDA's 15-year post-treatment follow-up requirement for gene therapies introduces long-term regulatory compliance burden
• • Competitive risk heightened by reliance on successful development of three ARC-SparX candidates ACLX-001, ACLX-002, ACLX-004 in upcoming trials
• • Liquidity risk: existing cash sufficient for 12 months, but accelerated capital consumption may necessitate dilutive financing or unfavorable collaborations

What are the latest ACLX SEC filings in 2026?

Arcellx, Inc. (ACLX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ACLX file its most recent 10-K annual report?

Arcellx, Inc. (ACLX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ACLX 10-Q quarterly reports?

Arcellx, Inc. (ACLX)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every ACLX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ACLX filed recently?

Arcellx, Inc. (ACLX)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ACLX insider trading activity (Form 4)?

SignalX aggregates every ACLX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ACLX file with the SEC?

Arcellx, Inc. (ACLX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ACLX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Arcellx, Inc. (ACLX).

What is ACLX's SEC CIK number?

Arcellx, Inc. (ACLX)'s SEC CIK (Central Index Key) number is 1786205. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1786205 to look up all ACLX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ACLX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Arcellx, Inc. (ACLX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.